Advertisement

Topics

Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

06:17 EDT 24th March 2017 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 972

Extremely Relevant

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 9, Authorised


Human medicines European public assessment report (EPAR): Ifirmasta (previously Irbesartan Krka), irbesartan, Revision: 8, Authorised

Propagermanium and irbesartan: Interim Phase II data


BRIEF-Zhejiang Hisun Pharmaceutical unit gets FDA approval

* Says its unit receives ANDA approval for its irbesartan and hydrochlorothiazide tablets from U.S Food and Drug Administration

Teva antihypertensive generic duo gets FDA thumbs up

Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) and Azor (amlodipine and olmesartan medoxomil). The Israeli company’s Azor generic has already launched in the US, while the Tribenzor generic has entered final pre-launch stages. read more

Thiazide-type diuretics may reduce risk of hip, pelvic fractures in adults with hypertension

After nearly five years of follow-up, adults with hypertension who received chlorthalidone had a 21 percent lower risk of hip and pelvic fractures compared with those who received lisinopril or amlodipine, according to a post hoc analysis of a randomized trial.

Relevant

BRIEF-Alembic Pharmaceuticals receives ANDA approval for drug to treat hypertension

* Alembic Pharmaceuticals Limited receives ANDA approval for Telmisartan and Amlodipine tablets Source text: [Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2016, title " Alembic Pharmaceutical...

Retraction: Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial

Human medicines European public assessment report (EPAR): Amlodipine / Valsartan Mylan , amlodipine / valsartan, Revision: 1, Authorised

Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study

FDA OKs Teva's generic hypertension drug

Teva Pharmaceutical Industries' generic version of Tribenzor tablets, or olmesartan medoxomil, amlodipine and hydrochlorothia -More- 

Generic hypertension drug from Ajanta Pharma hits US market

Ajanta Pharma has launched its amlodipine and olmesartan medoxomil tablets in the US market after receiving approval from the -More- 

Antihypertensive Drug "Micatrio® Combination Tablets"

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office: Tokyo; President and CEO: Yoshihiko Hatanaka, hereafter “Astellas”) announced today that the companies have newly launched “Micatrio® Combination Tablets,” a combina...

Dimerix key patent allowed in Japan for use of lead drug candidate in the treatment of kidney disease

MELBOURNE, Australia, 31 January 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the Japanese Patent Office has allowed a key patent covering the use of its lead compound DMX-200 for the treatment of kidney disease. The allowed claims und...

Antihypertensive Therapeutics in AsiaPacific Markets to 2021 Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Prices from USD $4995

Antihypertensive Therapeutics in AsiaPacific Markets to 2021 Increasing Prevalence of Hypertension Drives Market Growth despite Weak PipelineSummaryHypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate CAGR of 1.2% to 561 million in 2021 in ...

Short-term variability and nocturnal decline in ambulatory blood pressure in normotension, white-coat hypertension, masked hypertension and sustained hypertension: a population-based study of older individuals in Spain

Dimerix Completes Recruitment of Part A of its Phase 2 Trial of DMX-200 in Chronic Kidney Disease

MELBOURNE, Australia, 6 December 2016:  Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that it has completed recruitment of patients into Part A of its Phase 2 trial for DMX-200, an innovative new treatment chronic kidney disease that combi...

Europe's Hypertension Strategy: Charting a Different Course?

Europe's premier hypertension meeting spotlights the subtle ways in which hypertension treatment in Europe is charting a slightly different course from that seen on the other side of the Atlantic. Heartwire from Medscape

Black, Hispanic adults may have poorer hypertension control than white patients

Black and Hispanic patients with hypertension had poorer control of their condition compared with white patients with hypertension, according to a cross-sectional study. The researchers found the differences in hypertension were more pronounced in younger and uninsured patients.

Renal Denervation for Uncontrolled Hypertension

Is renal denervation an effective option for managing uncontrolled hypertension? Current Opinion in Nephrology and Hypertension

High prevalence, incidence of hypertension among rural Africans living with HIV

About 12 percent of people living with HIV in rural Tanzania have hypertension at the moment of HIV diagnosis. An additional 10 percent will develop hypertension during the first months of antiretroviral therapy. This represents an incidence 1.5 times higher than that found in Europe or the United States.

Genetic screening in arterial hypertension

Arterial hypertension is a complex condition influenced by multiple interrelated genetic and environmental factors. This Review examines our progress in unravelling the genetic determinants of hypertension, and the future use of genetic testing to personalize treatment and to improve the design of randomized controlled trials for the condition.

Dimerix Raises AU $2 million to Advance Clinical Program

Dimerix Limited (“Dimerix” or “the Company”) advises that it has received commitments for a placement to raise AU $2,000,000 (before costs) (Placement). 333,333,333 new shares will be issued to sophisticated and professional investors under the Placement at an issue price of AU $0.006 per share. Westar Capital Ltd acted as Lead Manager to the offer. The issue of shares...

Ajanta Pharma Announces the Launch of Amlodipine + Olmesartan Medoxomil Tablets

BRIDGEWATER, N.J., Nov. 2, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, India, announces today the launch of Amlodipine + Olmesartan Medoxomil Tablets, (5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg), a bioequivalent generic version of Azor®1 Tablets into the US market. Amlodipine + Olmesartan Medoxomil Tablets is part of an ever-growing ...

Hypertension: Thrombin amplification loop in hypertension


Quick Search
Advertisement
 

News Quicklinks